HR vi­o­la­tion push­es Re­vance co-founder out, vault­ing for­mer Zel­tiq chief to the helm

Months af­ter Re­vance amend­ed the terms of its Botox biosim­i­lar col­lab­o­ra­tion with My­lan, the Newark, Cal­i­for­nia-based drug de­vel­op­er dis­closed its co-founder Dan Browne is step­ping down, in what ap­pears to be mys­te­ri­ous cir­cum­stances.

The com­pa­ny — which is al­so de­vel­op­ing a ri­val to Al­ler­gan’s for­mi­da­ble Botox fran­chise — on Mon­day said Browne is de­part­ing “due to mis­judg­ment in han­dling an em­ploy­ee mat­ter,” that has al­so cul­mi­nat­ed in his res­ig­na­tion from Re­vance’s board of di­rec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER